Zhuhai Sailong Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
August 10, 2020 at 05:06 am
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 88.435 million compared to CNY 172.327 million a year ago. Operating loss was CNY 10.251 million compared to operating Income of CNY 24.436 million a year ago. Net loss was CNY 13.212 million compared to net income of CNY 20.223 million a year ago. Basic loss per share from continuing operations was CNY 0.0826 compared to basic earnings per share from continuing operations of CNY 0.1264 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
